...As we gather a more complete dataset over time, we expect these results to ultimately conclude that the impact of these drugs on the market should not only be manageable but ultimately help drive awareness of the disease and fuel an increase in the number of patients who ultimately are offered various forms of treatment in this case, positive airway pressure, Andrew wrote in a report published on April 18 based on a conversation with Carlos Nunez, MD, ResMeds chief medical officer, about the SURMOUNT-OSA trial results
Well discuss how it compares to other leading options later in this guide
Funct Bioinform 17:412425
Note one recurring literature trap: the dimer (CKPV) is a chemically different molecule with its own clinical record, and results attributed to it do not transfer to bare KPV, on which no human trials exist
17 The retrospective study found that subcutaneous semaglutide use was statistically significantly associated with the risk of developing NAION, no matter what the medications reason for use: patients with type 2 diabetes had a 4.28 HR compared to control (n=17 vs 6), while patients who used the medications for weight loss had a 7.64 HR compared to control (n=20 vs 3)
